112 related articles for article (PubMed ID: 12621776)
1. [Treatment of diabetes mellitus in patients after renal transplantation].
Wyzgał J; Paczek L; Senatorski G; Pilecki T; Gradowska L; Zegarska J
Pol Merkur Lekarski; 2002 Nov; 13 Suppl 1():16-9; discussion 19-20. PubMed ID: 12621776
[TBL] [Abstract][Full Text] [Related]
2. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study.
Ekberg H; Bernasconi C; Nöldeke J; Yussim A; Mjörnstedt L; Erken U; Ketteler M; Navrátil P
Nephrol Dial Transplant; 2010 Jun; 25(6):2004-10. PubMed ID: 20106825
[TBL] [Abstract][Full Text] [Related]
3. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis.
Zucker MJ; Baran DA; Arroyo LH; Goldstein DJ; Neacy C; Mele L; Weinberg AD; Prendergast TW; Ribner HS
Transplant Proc; 2005 Jun; 37(5):2231-9. PubMed ID: 15964386
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up after conversion from tacrolimus to cyclosporin in renal transplant patients with new-onset diabetes mellitus after transplantation.
Batista F; Auyanet I; Torregrosa JV; Oppenheimer F
Transplant Proc; 2012 Nov; 44(9):2582-4. PubMed ID: 23146461
[TBL] [Abstract][Full Text] [Related]
5. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
[TBL] [Abstract][Full Text] [Related]
6. Post-transplant diabetes mellitus: is it associated with poor allograft outcomes in renal transplants?
Choi JY; Kwon OJ
Transplant Proc; 2013 Oct; 45(8):2892-8. PubMed ID: 24156999
[TBL] [Abstract][Full Text] [Related]
7. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy.
Weir MR; Ward MT; Blahut SA; Klassen DK; Cangro CB; Bartlett ST; Fink JC
Kidney Int; 2001 Apr; 59(4):1567-73. PubMed ID: 11260422
[TBL] [Abstract][Full Text] [Related]
8. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial.
Zuckermann A; Reichenspurner H; Birsan T; Treede H; Deviatko E; Reichart B; Klepetko W
J Thorac Cardiovasc Surg; 2003 Apr; 125(4):891-900. PubMed ID: 12698153
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of the DIRECT study: a comparative assessment of the hyperglycemic effects of tacrolimus and cyclosporine following renal transplantation.
Vincenti F; Rostaing L;
Contemp Clin Trials; 2005 Feb; 26(1):17-24. PubMed ID: 15837449
[TBL] [Abstract][Full Text] [Related]
11. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years.
Cosio FG; Pesavento TE; Osei K; Henry ML; Ferguson RM
Kidney Int; 2001 Feb; 59(2):732-7. PubMed ID: 11168956
[TBL] [Abstract][Full Text] [Related]
12. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
13. Insulin requirement after a renal transplant in patients with type 2 diabetes: the choice of calcineurin inhibitors.
van den Hoogen MW; van der Hoeven AM; Hilbrands LB
Exp Clin Transplant; 2013 Jun; 11(3):234-8. PubMed ID: 23432070
[TBL] [Abstract][Full Text] [Related]
14. Influence of tacrolimus plus mycophenolate mofetil regimens on acute rejection rate and diabetes mellitus development in renal transplant recipients.
Demirbaş A; Tuncer M; Yavuz A; Gürkan A; Kaçar S; Cetinkaya R; Tekin S; Akbaş SH; Akaydin M; Ersoy F; Yakupoğlu G
Transplant Proc; 2004; 36(1):175-7. PubMed ID: 15013338
[TBL] [Abstract][Full Text] [Related]
15. Cancer Screening of Renal Transplant Patients Undergoing Long-Term Immunosuppressive Therapy.
Demir T; Ozel L; Gökçe AM; Ata P; Kara M; Eriş C; Özdemir E; Titiz MI
Transplant Proc; 2015 Jun; 47(5):1413-7. PubMed ID: 26093731
[TBL] [Abstract][Full Text] [Related]
16. Side effects of the calcineurin inhibitor, such as new-onset diabetes after kidney transplantation.
Borda B; Lengyel C; Várkonyi T; Kemény E; Ottlakán A; Kubik A; Keresztes C; Lázár G
Acta Physiol Hung; 2014 Sep; 101(3):388-94. PubMed ID: 25183511
[TBL] [Abstract][Full Text] [Related]
17. Clinical importance of insulin resistance after renal transplantation in patients on triple immunosuppressive therapy with cyclosporine, corticosteroids and mycophenolate mofetil.
Petkovska L; Ivanovski N; Dimitrovski C; Serafimoski V
Prilozi; 2008 Jul; 29(1):129-39. PubMed ID: 18709005
[TBL] [Abstract][Full Text] [Related]
18. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs.
Araki M; Flechner SM; Ismail HR; Flechner LM; Zhou L; Derweesh IH; Goldfarb D; Modlin C; Novick AC; Faiman C
Transplantation; 2006 Feb; 81(3):335-41. PubMed ID: 16477217
[TBL] [Abstract][Full Text] [Related]
19. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
[TBL] [Abstract][Full Text] [Related]
20. New-onset diabetes after transplantation--should it be a factor in choosing an immunosuppressant regimen for kidney transplant recipients.
Chadban S
Nephrol Dial Transplant; 2008 Jun; 23(6):1816-8. PubMed ID: 18326882
[No Abstract] [Full Text] [Related]
[Next] [New Search]
